Compare FXNC & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FXNC | AGEN |
|---|---|---|
| Founded | 1907 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.4M | 274.8M |
| IPO Year | 2012 | 1999 |
| Metric | FXNC | AGEN |
|---|---|---|
| Price | $29.40 | $8.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 17.8K | ★ 846.4K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.43% | N/A |
| EPS Growth | 96.00 | ★ 100.00 |
| EPS | ★ 1.17 | 0.96 |
| Revenue | $7,717,000.00 | ★ $42,877,086.00 |
| Revenue This Year | $12.21 | $107.63 |
| Revenue Next Year | $2.93 | N/A |
| P/E Ratio | $26.03 | ★ $9.06 |
| Revenue Growth | 7.40 | ★ 89.95 |
| 52 Week Low | $21.59 | $2.71 |
| 52 Week High | $33.24 | $8.85 |
| Indicator | FXNC | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
First National Corp is a bank holding company of First Bank, which is a commercial bank. Its core offering includes loans, deposits, wealth management, and other products and services. The Company operates through two reportable operating segments: Community Banking and wealth management. The Community Banking segment involves making loans and generating deposits from individuals, businesses, and charitable organizations. Wealth Management Services offers corporate trustee services, trust and estate administration, IRA administration and custody services. The company has revenue from Community Banking segment.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.